Cancer Immunotherapy Using Virus-like Particles
One major challenge in the development of effective cancer therapies is a lack of universal, cancer specific markers in target cells. The current standard therapies rely on surgery, chemotherapy, and radiation therapy. Such procedures lead to a population of resistant cancer cells that makes further applications of chemotherapy/radiation therapy ineffective. Additionally, the systemic application of chemotherapy lacks specificity and has off-target systemic effects that lead to adverse side effects. A considerable effort has been devoted to identifying and targeting specific extracellular cancer markers using antibody based therapies. However, diminished access to new cancer cell surface markers has limited the development of corresponding antibodies.
Investigators at the National Cancer Institute have discovered a novel method that employs presentation of intracellular cancer antigens on the cell surface to convert the tumor into induced antigen presenting cells. The technology utilizes virus-like particle (VLP)-mediated RNA delivery of therapeutic proteins, HLA II and CD80, to directly convert cancer cells into antigen presenting cells (APC) that activate helper and cytotoxic T cells against the tumor. This immunotherapy has the potential to induce tumor specific responses with minimal toxicity to healthy cells.
Competitive Advantages:
- Simple procedure for targeted delivery
- Therapy is effective for any cancer antigen, known or unknown
- More robust immune response
Commercial Applications:
- Cancer immunotherapy
- Cancer vaccine
Related Inventions
-
E-264-2011
TAB-4160
Virus-Like Particles That Can Deliver Proteins and RNA
Patents
- US
National Stage 15/104,785
Filed on 2016-06-15
Status: Abandoned - US
Provisional (PRV) 61/916,394
Filed on 2013-12-16
Status: Abandoned - Patent Cooperation Treaty
(PCT) PCT/US2014/070552
Filed on 2014-12-16
Status: Expired - Australia
National Stage 2014365777
Filed on 2014-12-16
Status: Issued - Canada
National Stage 2934075
Filed on 2014-12-16
Status: Issued - European Patent
National Stage 14824680.4
Filed on 2014-12-16
Status: Abandoned - Japan
National Stage 2016-558546
Filed on 2014-12-16
Status: Issued - Brazil
National Stage BR112016013804-0
Filed on 2014-12-16
Status: Abandoned - China
National Stage 201480074163.2
Filed on 2014-12-16
Status: Abandoned - Hong Kong
China Patent (CN) 17105504.9
Filed on 2017-06-02
Status: Abandoned - India
National Stage 201617023312
Filed on 2014-12-16
Status: Issued - South Korea
National Stage 10-2016-7019097
Filed on 2016-07-14
Status: Issued - Mexico
National Stage MX/a/2016/007726
Filed on 2014-12-16
Status: Issued - Singapore
National Stage 11201604868Y
Filed on 2014-12-16
Status: Issued - Singapore
Divisional (DIV) 10201811190S
Filed on 2018-12-14
Status: Pending - European Patent
Divisional (DIV) 20150087.3
Filed on 2020-01-02
Status: Issued - Japan
Divisional (DIV) 2020-001954
Filed on 2020-01-09
Status: Abandoned - US Patent 11,718,861
Filed on 2020-12-14
Status: Issued - India
Divisional (DIV) 202118011347
Filed on 2021-03-17
Status: Pending - European Patent
Divisional (DIV) 21190529.4
Filed on 2021-08-10
Status: Pending - China
Divisional (DIV) 202110829496.3
Filed on 2021-07-22
Status: Abandoned - Belgium
European patent (EP) 20150087.3
Filed on 2014-12-16
Status: Issued - Switzerland
European patent (EP) 20150087.3
Filed on 2014-12-16
Status: Issued - Germany
European patent (EP) 20150087.3
Filed on 2014-12-16
Status: Issued